Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Genetic Testing Could Identify HIV Patients At Risk Of Hypersensitivty To HIV Drug

01.03.2002


HIV patients at risk of a potentially fatal hypersensitive reaction to the antiretroviral drug abacavir could be identified by genetic testing before drug therapy has started, suggest authors of a fast-track study in this week’s issue of THE LANCET.



The use of the HIV antiretroviral drug abacavir, a potent HIV-1 nucleoside-analogue reverse-transcriptase inhibitor, is complicated by a potentially life-threatening hypersensitivity syndrome in about 5% of cases. Genetic factors influencing the immune response to abacavir might result in some individuals being more susceptible to a hypersensitive reaction than other patients.

Simon Mallal and colleagues from the Royal Perth Hospital, Australia, studied 200 HIV patients treated with abacavir. They focused on analysis of the MHC genes that are known to be associated with the immune response.


Abacavir hypersensitivity was identified in 18 patients, and drug tolerance was confirmed in 167 patients after 6 weeks of therapy. Patients with the allele (gene component) HLA-B*5701 were over 100 times more likely to be hypersensitive to abacavir; this allele was present in 14 (78%) of the 18 patients with abacavir hypersensitivity, and in four (2%) of the 167 abacavir-tolerant patients. The genetic region marked by the combination HLA-B*5701, HLA-DR7, and HLA-DQ3 (the 57.1 ancestral haplotype) was present in 13 (72%) hypersensitive patients and none of the tolerant patients. All patients with the full 57.1 ancestral haplotype experienced abacavir hypersensitivity.

Simon Mallal comments: “The findings have important clinical implications. In our population, withholding abacavir in patients with this haplotype would be expected to reduce the prevalence of this potentially life-threatening event from 9% to 2.5 % without inappropriately denying the drug to any patients. Based on these data it is our current practice to withhold abacavir in patients who have the HLA-B*5701,-DR7,-DQ3 haplotype. However, before such practice can be taken up by others it is essential that the association between HLA type and abacavir hypersensitivity in their own populations is assessed.”

He adds: “However, there were four patients in the study who developed abacavir hypersensitivity in whom no part of the susceptibility haplotype could be identified. Therefore, HLA typing at these alleles could not be used to completely exclude the risk of a future reaction, and the current clinical approach of high vigilance for these reactions must continue.”

In an accompanying Commentary (p 722), Amalio Telenti from University Hospital, Lausanne, Switzerland,concludes: “From recent developments in human genetics, a need for a more comprehensive analysis, including dozens or hundreds of genes, can be predicted. This analysis may become feasible by use of microarrays that allow interrogation of multiple genes simultaneously. Decisions about the best time to start therapy, and the most effective and least toxic drug combinations, may be based on particular genotype profiles. This projection may look far-fetched, with just a few relevant genes identified, but these are the first drops before a downpour.”

Richard Lane | alphagalileo

More articles from Health and Medicine:

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

nachricht Study advances gene therapy for glaucoma
17.01.2018 | University of Wisconsin-Madison

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Polymers Based on Boron?

18.01.2018 | Life Sciences

Bioengineered soft microfibers improve T-cell production

18.01.2018 | Life Sciences

World’s oldest known oxygen oasis discovered

18.01.2018 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>